Evidence for fibroblast growth factor-2 as a mediator of amphetamine-enhanced motor improvement following stroke

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Wolf, William A ^a,c   Martin, Jody L ^b   Kartje, Gwendolyn L ^a,b   Farrer, Robert G ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; DEXAMPHETAMINE; FIBROBLAST GROWTH FACTOR 2; ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG MECHANISM; IN VITRO STUDY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE FIBER GROWTH; NERVE SPROUTING; NONHUMAN; NORADRENERGIC SYSTEM; PHYSIOTHERAPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PYRAMIDAL NERVE CELL; RAT; ANIMAL; CONVALESCENCE; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; NERVE FIBER; NEURITE; PATHOLOGY; PATHOPHYSIOLOGY; TIME; UPREGULATION;

ADRENERGIC AGONISTS; AMPHETAMINE; ANIMALS; AXONS; FIBROBLAST GROWTH FACTOR 2; MALE; MOTOR ACTIVITY; NEURITES; PYRAMIDAL CELLS; RATS; RECEPTORS, ADRENERGIC, ALPHA-1; RECOVERY OF FUNCTION; STROKE; TIME FACTORS; UP-REGULATION;

EID: 84907221232     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108031     Document Type: Article

References (65)

1. American Heart Association (2010) Heart Disease and Stroke Statistics - 2010 Update. American Heart Association, Dallas, TX.
2. Harvey RL (2003) Motor recovery after stroke: new directions in scientific inquiry. Phys Med Rehabil Clin N Am 14: S1-S5.
3. Calautti C, Baron JC (2003) Functional neuroimaging studies of motor recovery after stroke in adults: a review. Stroke 34: 1553-1566.
4. Nudo RJ, Plautz EJ, Frost SB (2001) Role of adaptive plasticity in recovery of function after damage to motor cortex. Muscle Nerve 24: 1000-1019.
5. Teasell R, Bayona N, Salter K, Hellings C, Bitensky J (2006) Progress in clinical neurosciences: stroke recovery and rehabilitation. Can J Neurol Sci 33: 357-364.
6. Robinson TE, Kolb B (2004) Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology 47 Suppl 1: 33-46.
7. Shaw-Lutchman TZ, Impey S, Storm D, Nestler EJ (2003) Regulation of CREmediated transcription in mouse brain by amphetamine. Synapse 48: 10-17.
8. Biernaskie J, Corbett D (2001) Enriched rehabilitative training promotes improved forelimb motor function and enhanced dendritic growth after focal ischemic injury. J Neurosci 21: 5272-5280.
9. Vaynman S, Gomez-Pinilla F (2005) License to run: exercise impacts functional plasticity in the intact and injured central nervous system by using neurotrophins. Neurorehabil Neural Repair 19: 283-295.
10. Ang ET, Gomez-Pinilla F (2007) Potential therapeutic effects of exercise to the brain. Curr Med Chem 14: 2564-2571.
11. Chen MJ, Russo-Neustadt AA (2009) Running exercise-induced up-regulation of hippocampal brain-derived neurotrophic factor is CREB-dependent. Hippocampus.
12. Forrester LW, Wheaton LA, Luft AR (2008) Exercise-mediated locomotor recovery and lower-limb neuroplasticity after stroke. J Rehabil Res Dev 45: 205-220.
13. Kuczenski R, Segal DS, Cho AK, Melega W (1995) Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15: 1308-1317.
14. Gilmour G, Iversen SD, O'Neill MF, O'Neill MJ, Ward MA, et al. (2005) Amphetamine promotes task-dependent recovery following focal cortical ischaemic lesions in the rat. Behav Brain Res 165: 98-109.
15. Goldstein LB (2003) Amphetamines and related drugs in motor recovery after stroke. Phys Med Rehabil Clin N Am 14: S125-34, x.
16. Goldstein LB, Davis JN (1990) Influence of lesion size and location on amphetamine-facilitated recovery of beam-walking in rats. Behav Neurosci 104: 320-327.
17. Martinsson L, Hardemark H, Eksborg S (2007) Amphetamines for improving recovery after stroke. Cochrane Database Syst Rev CD002090.
18. Papadopoulos CM, Tsai SY, Guillen V, Ortega J, Kartje GL, et al. (2009) Motor recovery and axonal plasticity with short-term amphetamine after stroke. Stroke 40: 294-302.
19. Walker-Batson D (2013) Amphetamine and post-stroke rehabilitation: indications and controversies. Eur J Phys Rehabil Med 49: 251-260.
20. Beltran EJ, Papadopoulos CM, Tsai SY, Kartje GL, Wolf WA (2010) Long-term motor improvement after stroke is enhanced by short-term treatment with the alpha-2 antagonist, atipamezole. Brain Res 1346: 174-182.
21. Rosser N, Floel A (2008) Pharmacological enhancement of motor recovery in subacute and chronic stroke. NeuroRehabilitation 23: 95-103.
22. Goldstein LB (2009) Amphetamine trials and tribulations. Stroke 40: S133-S135.
23. Takami K, Iwane M, Kiyota Y, Miyamoto M, Tsukuda R, et al. (1992) Increase of basic fibroblast growth factor immunoreactivity and its mRNA level in rat brain following transient forebrain ischemia. Exp Brain Res 90: 1-10.
24. Takami K, Kiyota Y, Iwane M, Miyamoto M, Tsukuda R, et al. (1993) Upregulation of fibroblast growth factor-receptor messenger RNA expression in rat brain following transient forebrain ischemia. Exp Brain Res 97: 185-194.
25. Reilly JF, Kumari VG (1996) Alterations in fibroblast growth factor receptor expression following brain injury. Exp Neurol 140: 139-150.
26. Wei OY, Huang YL, Da CD, Cheng JS (2000) Alteration of basic fibroblast growth factor expression in rat during cerebral ischemia. Acta Pharmacol Sin 21: 296-300.
27. Kawamata T, Dietrich WD, Schallert T, Gotts JE, Cocke RR, et al. (1997) Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction. Proc Natl Acad Sci U S A 94: 8179-8184.
28. Kawamata T, Alexis NE, Dietrich WD, Finklestein SP (1996) Intracisternal basic fibroblast growth factor (bFGF) enhances behavioral recovery following focal cerebral infarction in the rat. J Cereb Blood Flow Metab 16: 542-547.
29. Rowntree S, Kolb B (1997) Blockade of basic fibroblast growth factor retards recovery from motor cortex injury in rats. Eur J Neurosci 9: 2432-2441.
30. Flores C, Rodaros D, Stewart J (1998) Long-lasting induction of astrocytic basic fibroblast growth factor by repeated injections of amphetamine: blockade by concurrent treatment with a glutamate antagonist. J Neurosci 18: 9547-9555.
31. Flores C, Samaha AN, Stewart J (2000) Requirement of endogenous basic fibroblast growth factor for sensitization to amphetamine. J Neurosci 20: RC55.
32. McCarthy KD, de VJ (1980) Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85: 890-902.
33. Flores C, Stewart J (2000) Changes in astrocytic basic fibroblast growth factor expression during and after prolonged exposure to escalating doses of amphetamine. Neuroscience 98: 287-293.
34. Kwon JH, Vogt Weisenhorn DM, Downen M, Ruan K, Roback L, et al. (1998) Beta-adrenergic and fibroblast growth factor receptors induce neuronal process outgrowth through different mechanisms. Eur J Neurosci 10: 2776-2789.
35. Hausott B, Schlick B, Vallant N, Dorn R, Klimaschewski L (2008) Promotion of neurite outgrowth by fibroblast growth factor receptor 1 overexpression and lysosomal inhibition of receptor degradation in pheochromocytoma cells and adult sensory neurons. Neuroscience 153: 461-473.
36. Kuczenski R, Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68: 2032-2037.
37. Krobert KA, Sutton RL, Feeney DM (1994) Spontaneous and amphetamineevoked release of cerebellar noradrenaline after sensorimotor cortex contusion: an in vivo microdialysis study in the awake rat. J Neurochem 62: 2233-2240.
38. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, et al. (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
39. Riva MA, Molteni R, Racagni G (1998) Differential regulation of FGF-2 and FGFR-1 in rat cortical astrocytes by dexamethasone and isoproterenol. Brain Res Mol Brain Res 57: 38-45.
40. Gilardino A, Farcito S, Zamburlin P, Audisio C, Lovisolo D (2009) Specificity of the second messenger pathways involved in basic fibroblast growth factorinduced survival and neurite growth in chick ciliary ganglion neurons. J Neurosci Res 87: 2951-2962.
41. Jeon CY, Kim HJ, Morii H, Mori N, Settleman J, et al. (2010) Neurite outgrowth from PC12 cells by basic fibroblast growth factor (bFGF) is mediated by RhoA inactivation through p190RhoGAP and ARAP3. J Cell Physiol 224: 786-794.
42. Zamburlin P, Ruffinatti FA, Gilardino A, Farcito S, Parrini M, et al. (2013) Calcium signals and FGF-2 induced neurite growth in cultured parasympathetic neurons: spatial localization and mechanisms of activation. Pflugers Arch 465: 1355-1370.
43. Day JS, O'Neill E, Cawley C, Aretz NK, Kilroy D, et al. (2014) Noradrenaline acting on astrocytic beta(2)-adrenoceptors induces neurite outgrowth in primary cortical neurons. Neuropharmacology 77:234-48. doi: 10.1016/j.neuropharm. 2013.09.027. Epub;%2013 Oct 12.: 234-248.
44. Gobert A, Billiras R, Cistarelli L, Millan MJ (2004) Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors. J Neurosci Methods 140: 141-152.
45. Detillieux KA, Meij JT, Kardami E, Cattini PA (1999) alpha1-Adrenergic stimulation of FGF-2 promoter in cardiac myocytes and in adult transgenic mouse hearts. Am J Physiol 276: H826-H833.
46. Kajitani N, Hisaoka-Nakashima K, Morioka N, Okada-Tsuchioka M, Kaneko M, et al. (2012) Antidepressant acts on astrocytes leading to an increase in the expression of neurotrophic/growth factors: differential regulation of FGF-2 by noradrenaline. PLoS One 7: e51197.
47. Feeney DM, De Smet AM, Rai S (2004) Noradrenergic modulation of hemiplegia: facilitation and maintenance of recovery. Restor Neurol Neurosci 22: 175-190.
48. Feeney DM (1997) From laboratory to clinic: noradrenergic enhancement of physical therapy for stroke or trauma patients. Adv Neurol 73: 383-394.
49. Goldstein LB (2003) Pharmacotherapy in stroke rehabilitation. Adv Neurol 92: 447-450.
50. Cheung VC, Deboer C, Hanson E, Tunesi M, D'Onofrio M, et al. (2013) Gene expression changes in the motor cortex mediating motor skill learning. PLoS One 8: e61496.
51. Ma YP, Ma MM, Cheng SM, Ma HH, Yi XM, et al. (2008) Intranasal bFGFinduced progenitor cell proliferation and neuroprotection after transient focal cerebral ischemia. Neurosci Lett 437: 93-97.
52. Alzheimer C, Werner S (2002) Fibroblast growth factors and neuroprotection. Adv Exp Med Biol 513:335-51.: 335-351.
53. Li Q, Stephenson D (2002) Postischemic administration of basic fibroblast growth factor improves sensorimotor function and reduces infarct size following permanent focal cerebral ischemia in the rat. Exp Neurol 177: 531-537.
54. Ren JM, Finklestein SP (2005) Growth factor treatment of stroke. Curr Drug Targets CNS Neurol Disord 4: 121-125.
55. Sugimori H, Speller H, Finklestein SP (2001) Intravenous basic fibroblast growth factor produces a persistent reduction in infarct volume following permanent focal ischemia in rats. Neurosci Lett 300: 13-16.
56. Paciaroni M, Bogousslavsky J (2011) Trafermin for stroke recovery: is it time for another randomized clinical trial? Expert Opin Biol Ther 11: 1533-1541.
57. Bogousslavsky J, Victor SJ, Salinas EO, Pallay A, Donnan GA, et al. (2002) Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc Dis 14: 239-251.
58. Jakala P, Jolkkonen J (2012) Time for a neurorestorative therapy in stroke. Expert Opin Biol Ther 12: 267-270.
59. Phillips JP, Devier DJ, Feeney DM (2003) Rehabilitation pharmacology: bridging laboratory work to clinical application. J Head Trauma Rehabil 18: 342-356.
60. Gladstone DJ, Black SE (2000) Enhancing recovery after stroke with noradrenergic pharmacotherapy: a new frontier? Can J Neurol Sci 27: 97-105.
61. Bachis A, Mallei A, Cruz MI, Wellstein A, Mocchetti I (2008) Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons. Neuropharmacology 55: 1114-1120.
62. Mallei A, Shi B, Mocchetti I (2002) Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal neurons. Mol Pharmacol 61: 1017-1024.
63. Zittel S, Weiller C, Liepert J (2007) Reboxetine improves motor function in chronic stroke. A pilot study. J Neurol 254: 197-201.
64. Bilge C, Kocer E, Kocer A, Turk BU (2008) Depression and functional outcome after stroke: the effect of antidepressant therapy on functional recovery. Eur J Phys Rehabil Med 44: 13-18.
65. Chen Y, Guo JJ, Zhan S, Patel NC (2006) Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. Ann Pharmacother 40: 2115-2122.